title: Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case-Control Study.
abstract: BACKGROUND
  Tight control of severe rheumatoid arthritis (RA) in patients with high disease activity, even when using biologics, is sometimes difficult using a treat-to-target strategy. Switching from one biologic to another is associated with lower efficacy than that in treatment-naive cases. We developed the K-method that involves simultaneous treatment with golimumab and intra-articular joint injection of triamcinolone acetonide (TA) in patients undergoing switching of biologics. We performed this retrospective case-control study to investigate the efficacy of achieving an immediate treatment response using the K-method.
  
  
  METHODS
  This study involved 20 patients with RA (control group, 10 patients; K-method group, 10 patients). Patients in the control group were switched to golimumab from other biologics without intra-articular injection of TA. The K-method involved injection of 1 mL of TA (40 mg/mL) and 2 mL of 1% lidocaine hydrochloride into swollen or painful joints on the same day as golimumab treatment. A quick response one day after treatment was compared between the two groups according to the disease activity score 28 based on C-reactive protein (DAS28 CRP), clinical disease activity index (CDAI), simplified disease activity index (SDAI), European League Against Rheumatism (EULAR) response, and remission rate. These parameters were investigated for 24 weeks.
  
  
  RESULTS
  The K-method group showed significant improvements in DAS28 CRP, CDAI, and SDAI at one day, 12 weeks, and 24 weeks compared with the control group. The number of swollen and tender joints and the patient and doctor global visual analog scale scores were also significantly different between the two groups. The remission rates based on DAS28 CRP were 30% at one day, 50% at 12 weeks, and 60% at 24 weeks in the K-method group. The EULAR good/moderate response rates were 80% at one day, 90% at 12 weeks, and 90% at 24 weeks in the K-method group; however, these rates were only 10%, 40%, and 40%, respectively, in the control group. No adverse events occurred in either group.
  
  
  CONCLUSIONS
  Simultaneous treatment with biologics and intra-articular injection of TA is useful for cases involving switching of biologics for RA. This strategy is safe and practical for RA treatment.
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Kanbe
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Junji
authors.initials: J
authors.lastname: Chiba
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Inoue
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Taguchi
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Yabuki
authors.affiliation: Department of Orthopedic Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Deguchi
keywords: biologics; injection; rheumatoid arthritis; triamcinolone acetonide